INVAC1-CT-201: A Phase II Study of INVAC-1 Treatment of Patients with High-Risk Chronic Lymphocytic Leukemia
MD Anderson Study Status
Phase 2 study to assess the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptas (hTERT) protein, at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD) eradication rate in the bone marrow, either as a single agent in a high risk "watch and wait" group (group 1 - 42 patients) or in combination with ibrutinib (group 2 - 42 patients), in patients with Chronic Lymphocytic Leukemia (CLL). Pharmacodynamics and safety will also be assessed.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Leukemia, Lymphocytic, Chronic, B-Cell
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.